WallStreetZenWallStreetZen

NASDAQ: APLS
Apellis Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for APLS

Based on 15 analysts offering 12 month price targets for Apellis Pharmaceuticals Inc

Min Forecast
$18.00-20.28%
Avg Forecast
$34.53+52.94%
Max Forecast
$52.00+130.29%

Should I buy or sell APLS stock?

Based on 15 analysts offering ratings for Apellis Pharmaceuticals Inc.

Buy
Strong Buy
7 analysts 46.67%
Buy
4 analysts 26.67%
Hold
3 analysts 20%
Sell
0 analysts 0%
Strong Sell
1 analysts 6.67%
Our proven Zen Rating quant model agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their APLS stock forecasts and price targets.

APLS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-28
lockedlocked$00.00+00.00%2026-01-21
lockedlocked$00.00+00.00%2026-01-20
lockedlocked$00.00+00.00%2026-01-13
lockedlocked$00.00+00.00%2026-01-13
Stifel Nicolaus
Top 8%
93
Strong BuyMaintains$48.00+112.58%2025-12-19
JP Morgan
Top 4%
97
Strong BuyMaintains$36.00+59.43%2025-11-05
Mizuho
Top 7%
94
HoldMaintains$19.00-15.85%2025-11-03
Citigroup
Top 10%
91
Strong BuyMaintains$45.00+99.29%2025-10-31
TD Cowen
Top 17%
84
Strong BuyMaintains$45.00+99.29%2025-10-31

1 of 2

Forecast return on equity

Is APLS forecast to generate an efficient return?

Company
57.08%
Industry
352.12%
Market
211.34%
APLS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is APLS forecast to generate an efficient return on assets?

Company
21.63%
Industry
122.26%
APLS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

APLS earnings per share forecast

What is APLS's earnings per share in the next 3 years based on estimates from 21 analysts?

Avg 1 year Forecast
-$1.13-423.94%
Avg 2 year Forecast
-$0.13-136.29%
Avg 3 year Forecast
$0.85+143.91%
APLS's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

APLS revenue forecast

What is APLS's revenue in the next 3 years based on estimates from 22 analysts?

Avg 1 year Forecast
$883.9M-13.04%
Avg 2 year Forecast
$1.1B+3.31%
Avg 3 year Forecast
$1.3B+26.03%
APLS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

APLS earnings growth forecast

How is APLS forecast to perform vs Biotechnology companies and vs the US market?

Company
34.96%
Industry
69.84%
Market
39.88%
APLS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
APLS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
APLS's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

APLS revenue growth forecast

How is APLS forecast to perform vs Biotechnology companies and vs the US market?

Company
7.61%
Industry
116.92%
Market
23.08%
APLS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
APLS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

APLS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
APLS$22.58$34.53+52.94%Buy
ADPT$18.50$18.57+0.38%Strong Buy
IDYA$32.19$50.18+55.89%Strong Buy
BEAM$27.62$41.83+51.46%Buy
IRON$77.32$119.14+54.09%Strong Buy
View Top Biotech Stocks

Apellis Pharmaceuticals Stock Forecast FAQ

Is Apellis Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 15 Wall Street analysts covering (NASDAQ: APLS) stock is to Buy APLS stock.

Out of 15 analysts, 7 (46.67%) are recommending APLS as a Strong Buy, 4 (26.67%) are recommending APLS as a Buy, 3 (20%) are recommending APLS as a Hold, 0 (0%) are recommending APLS as a Sell, and 1 (6.67%) are recommending APLS as a Strong Sell.

If you're new to stock investing, here's how to buy Apellis Pharmaceuticals stock.

What is APLS's earnings growth forecast for 2026-2028?

(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual earnings growth rate of 34.96% is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.

Apellis Pharmaceuticals's earnings in 2026 is $44,986,000.On average, 21 Wall Street analysts forecast APLS's earnings for 2026 to be -$143,454,292, with the lowest APLS earnings forecast at -$233,110,062, and the highest APLS earnings forecast at $56,063,324. On average, 20 Wall Street analysts forecast APLS's earnings for 2027 to be -$16,068,703, with the lowest APLS earnings forecast at -$193,431,753, and the highest APLS earnings forecast at $325,220,420.

In 2028, APLS is forecast to generate $108,014,579 in earnings, with the lowest earnings forecast at -$50,837,833 and the highest earnings forecast at $379,955,230.

What is APLS's revenue growth forecast for 2026-2028?

(NASDAQ: APLS) Apellis Pharmaceuticals's forecast annual revenue growth rate of 7.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.

Apellis Pharmaceuticals's revenue in 2026 is $1,016,397,000.On average, 22 Wall Street analysts forecast APLS's revenue for 2026 to be $111,831,844,434, with the lowest APLS revenue forecast at $97,661,020,018, and the highest APLS revenue forecast at $126,904,793,654. On average, 20 Wall Street analysts forecast APLS's revenue for 2027 to be $132,851,478,900, with the lowest APLS revenue forecast at $114,038,444,236, and the highest APLS revenue forecast at $159,295,249,462.

In 2028, APLS is forecast to generate $162,078,804,258 in revenue, with the lowest revenue forecast at $126,189,926,172 and the highest revenue forecast at $195,481,461,810.

What is APLS's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: APLS) forecast ROA is 21.63%, which is lower than the forecast US Biotechnology industry average of 122.26%.

What is APLS's Price Target?

According to 15 Wall Street analysts that have issued a 1 year APLS price target, the average APLS price target is $34.53, with the highest APLS stock price forecast at $52.00 and the lowest APLS stock price forecast at $18.00.

On average, Wall Street analysts predict that Apellis Pharmaceuticals's share price could reach $34.53 by Jan 28, 2027. The average Apellis Pharmaceuticals stock price prediction forecasts a potential upside of 52.94% from the current APLS share price of $22.58.

What is APLS's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: APLS) Apellis Pharmaceuticals's current Earnings Per Share (EPS) is $0.35. On average, analysts forecast that APLS's EPS will be -$1.13 for 2026, with the lowest EPS forecast at -$1.84, and the highest EPS forecast at $0.44. On average, analysts forecast that APLS's EPS will be -$0.13 for 2027, with the lowest EPS forecast at -$1.53, and the highest EPS forecast at $2.57. In 2028, APLS's EPS is forecast to hit $0.85 (min: -$0.40, max: $3.00).

What is APLS's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: APLS) forecast ROE is 57.08%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.